About Us

Laser Focus World is an industry bedrock—first published in 1965 and still going strong. We publish original articles about cutting-edge advances in lasers, optics, photonics, sensors, and quantum technologies, as well as test and measurement, and the shift currently underway to usher in the photonic integrated circuits, optical interconnects, and copackaged electronics and photonics to deliver the speed and efficiency essential for data centers of the future.

Our 80,000 qualified print subscribers—and 130,000 12-month engaged online audience—trust us to dive in and provide original journalism you won’t find elsewhere covering key emerging areas such as laser-driven inertial confinement fusion, lasers in space, integrated photonics, chipscale lasers, LiDAR, metasurfaces, high-energy laser weaponry, photonic crystals, and quantum computing/sensors/communications. We cover the innovations driving these markets.

Laser Focus World is part of Endeavor Business Media, a division of EndeavorB2B.

Laser Focus World Membership

Never miss any articles, videos, podcasts, or webinars by signing up for membership access to Laser Focus World online. You can manage your preferences all in one place—and provide our editorial team with your valued feedback.

Magazine Subscription

Can you subscribe to receive our print issue for free? Yes, you sure can!

Newsletter Subscription

A Laser Focus World newsletter subscription is free to qualified professionals:

The Daily Beam

Showcases the newest content from Laser Focus World, including photonics- and optics-based applications, components, research, and trends. (Daily)

Product Watch

The latest in products within the photonics industry. (9x per year)

Bio & Life Sciences Product Watch

The latest in products within the biophotonics industry. (4x per year)

Laser Processing Product Watch

The latest in products within the laser processing industry. (3x per year)

Get Published!

If you’d like to write an article for us, reach out with a short pitch to Sally Cole Johnson: [email protected]. We love to hear from you.

Photonics Hot List

Laser Focus World produces a video newscast that gives a peek into what’s happening in the world of photonics.

Following the Photons: A Photonics Podcast

Following the Photons: A Photonics Podcast dives deep into the fascinating world of photonics. Our weekly episodes feature interviews and discussions with industry and research experts, providing valuable perspectives on the issues, technologies, and trends shaping the photonics community.

Social Media

Bluesky • Facebook • Instagram • LinkedIn • YouTube

Meet the Laser Focus World Team

Editorial

Sales

Editorial Advisory Board

  • Professor Andrea M. Armani, University of Southern California
  • Ruti Ben-Shlomi, Ph.D., LightSolver
  • James Butler, Ph.D., Hamamatsu
  • Natalie Fardian-Melamed, Ph.D., Columbia University
  • Justin Sigley, Ph.D., AmeriCOM
  • Professor Birgit Stiller, Max Planck Institute for the Science of Light, and Leibniz University of Hannover
  • Professor Stephen Sweeney, University of Glasgow
  • Mohan Wang, Ph.D., University of Oxford
  • Professor Xuchen Wang, Harbin Engineering University
  • Professor Stefan Witte, Delft University of Technology
My Watchlist
Indicators
Industrial Laser Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Clairity Founder Dr. Connie Lehman Named to Forbes 50 Over 50 Innovation List

By: via Business Wire

Recognition highlights Clairity’s mission to shift breast cancer care from late-stage treatment to proactive prevention

Clairity, Inc., a company pioneering AI-powered risk prediction in human health, today announced that Founder Dr. Connie Lehman has been named to the Forbes “50 Over 50: Innovation” list. This annual ranking celebrates women who are breaking boundaries and advancing bold solutions to global challenges. Dr. Lehman will be honored at the Forbes & Mika Brzezinski 50 Over 50 Celebration on November 4, 2025, in New York City.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251015827825/en/

Dr. Connie Lehman, Founder of Clairity

Dr. Connie Lehman, Founder of Clairity

Why This Matters

Breast cancer remains the most common cancer among women worldwide, and most women diagnosed have no family history of the disease. Early identification of women at higher risk is critical because it allows healthcare providers to recommend more personalized screening and prevention strategies. By applying AI directly to a woman’s routine mammogram, CLAIRITY BREAST can provide risk information that is more precise and equitable than traditional models, helping ensure that every woman gets the right care at the right time.

Dr. Lehman founded Clairity in 2020 to transform breast cancer care by shifting the focus from reactive diagnosis to proactive prevention. Earlier this year, Clairity achieved a major milestone when the U.S. Food and Drug Administration (FDA) granted De Novo authorization to CLAIRITY BREAST, the first FDA-authorized platform to predict five-year breast cancer risk from a routine screening mammogram.

“This honor reflects the collective effort of scientists, clinicians, and innovators applying AI to serve humanity — and, in this case, to confront the global challenge of breast cancer,” said Dr. Lehman. “Traditional risk models have been limited by the data and populations on which they were built. With CLAIRITY BREAST, we’re ensuring every woman, regardless of race or ethnicity, can receive risk information that is both accurate and equitable. Bringing this technology into healthcare systems this year is a critical step toward truly personalized and preventive care.”

Internationally recognized as a leader in breast imaging and cancer risk assessment, Dr. Lehman has authored more than 300 peer-reviewed publications spanning computer-aided diagnosis, deep learning, risk modeling, and advancements in breast cancer screening and diagnosis. She is Professor of Radiology at Harvard Medical School and a Breast Imaging Specialist at Mass General Brigham.

About CLAIRITY BREAST

CLAIRITY BREAST, authorized by the FDA under the name Allix5, is a mammography-based AI risk prediction platform that analyzes imaging data at the pixel level to identify individuals at elevated risk of future breast cancer. The AI model behind CLAIRITY BREAST was developed using 421,499 mammograms from 27 facilities across Europe, South America, and the U.S., and validated on more than 120,000 mammograms from ten geographically distinct U.S. screening centers, representing a diverse patient population. Validation was anchored in five-year outcome data. To learn more about indications for use, visit: https://clairity.com/clairity-breast/

About Clairity

Founded in 2020 and headquartered in Boston, Massachusetts, Clairity, Inc. is transforming healthcare risk assessment through the power of artificial intelligence and deep learning. Backed by Santé Ventures, ACE Global Equity, and Breast Cancer Research Foundation, Clairity's platform can uncover subtle patterns in routine images that are invisible to the human eye, enhancing risk prediction to empower clinicians and their patients with actionable, personalized insights. Clairity’s mission is to shift the standard of care from late-stage treatment to proactive prevention across human health. To learn more, visit us at www.clairity.com | LinkedIn

Dr. Lehman will be honored at the Forbes & Mika Brzezinski 50 Over 50 Celebration on November 4, 2025, in New York City.

Contacts

More News

View More
Advanced Micro Devices Eyes $300 as AI Demand Surges
Via MarketBeat
Topics Artificial Intelligence
Tickers AMD AMZN GOOGL MSFT NVDA ORCL
Qualcomm: What Last Friday’s Drop Says About Its Q4 Prospects
Via MarketBeat
Tickers AMD NVDA QCOM
3 Rare Earth Stocks Powering America’s Critical Minerals Boom
Via MarketBeat
Topics Artificial Intelligence Economy
Tickers CRML LAC MP
Why Analysts Are Upgrading Ratings After Klarna's IPO
Via MarketBeat
Topics Initial Public Offering
Tickers AFRM BAC GAP JPM KLAR WMT
Palantir’s New Healthcare Deal Boosts AI and Data Reach
Via MarketBeat
Topics Artificial Intelligence
Tickers ONMD PLTR
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.